New Drug Application submitted to FDA for oteseconazole for recurrent vulvovaginal candidiasis

Oteseconazole is an oral 14α-demethylase (CYP51) inhibitor antifungal agent currently under investigation. The application is supported by data from the VIOLET and ultraVIOLET Phase 3 clinical trials, which found that recurrence was reduced by 90% of patients over 1 year.

Source:

Biospace Inc.